| Abstrakt: |
Researchers have submitted a patent application for agents that target telomerase reverse transcriptase (TERT) to treat cancer and sensitize cancer cells to genotoxic therapy. The technology focuses on compounds, compositions, and methods for treating diseases associated with telomerase activity, particularly cell proliferative diseases like cancer. By inhibiting TERT, the compounds aim to overcome resistance to genotoxic therapy, sensitize patients to therapies, and enhance immune responses, potentially leading to improved treatment outcomes for various cancers. [Extracted from the article] |
